An interventional study of Nd:YAG laser and Diode laser in Nd:YAG Laser, Sclerotherapy and Diode Laser, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.
Reticular veins and telangiectasias (spider veins) represent common chronic venous disorders affecting a large proportion of the adult population, particularly women.
The Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique has emerged as an innovative method combining transdermal laser therapy, injection sclerotherapy, and skin cooling. This multimodal approach enhances visualization of feeder veins using augmented reality or vein illumination systems, allowing precise targeting and improved clearance rates. Cooling reduces pain and protects the epidermis, making the procedure more tolerable and safer.
Nd:YAG laser (1064 nm) is considered the cornerstone of the CLaCS technique due to its deeper penetration and selective photothermolysis of hemoglobin. It effectively targets deeper reticular veins (up to 3-4 mm depth), induces vessel wall contraction, and facilitates subsequent sclerotherapy.
69 studies on the registry are indexed under Telangiectasis; 12 are open to participants now.
This study's planned enrollment of 80 is above the median of 30 across 59 interventional studies indexed under Telangiectasis.
Browse Telangiectasis studies →Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).
Device: Nd:YAG laser
Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).
Drug: Diode laser
Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).
Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).
Degree of vein clearance
Degree of vein clearance will be assessed by immediate endpoint response during laser application, defined as either instantaneous disappearance of the vein or an immediate change in vein color.
Time frame: 6 months postoperatively
Degree of pain
Each patient will be instructed about postoperative pain assessment with VAS. VAS (0 represents "no pain" while 10 represents "the worst pain imaginable").
Time frame: 6 months postoperatively
Degree of patient satisfaction
Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).
Time frame: 6 months postoperatively
Incidence of complications
Incidence of complications such as hyperpigmentation, burns, and matting will be recorded.
Time frame: 6 months postoperatively
Number of treatment sessions required
Number of treatment sessions required will be recorded.
Time frame: 6 months postoperatively
Recurrence rate
Recurrence rate will be recorded.
Time frame: 6 months postoperatively
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 14 interventional studies with no phase under Telangiectasis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.